Log in

BPTH Bio-Path Holdings, Inc. OTC · United States

Bio-Path Holdings (BPTH) news BPTH reverse split, delisting and offering news

Latest Bio-Path Holdings news

  1. Company Updates

    Bio-Path cancels planned reverse split and approves treasury plan

    The company canceled a previously approved 1-30 reverse split and its board approved a digital asset treasury and a share of a court judgment held by its chief executive.

  2. Listings

    Nasdaq files Form 25 to remove Bio-Path Holdings common stock from listing

    Nasdaq Stock Market LLC filed a Form 25 notification dated July 11, 2025 to strike Bio-Path Holdings' common stock from listing and registration. The notice cites Exchange Act Rule 12d2-2(b), which covers removals the exchange initiates, and it does not give the reason.

Bio-Path Holdings annual financials

LineFY2024FY2023
Research and development$7.3 million$11.6 million
Net income (loss)-$9.9 million-$16.1 million
Cash from operations-$10.6 million-$11.5 million
Cash and equivalents$1.2 million$1.1 million

Latest balance sheet, Mar 31, 2026 (10-Q): cash and equivalents $12,000.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about Bio-Path Holdings

Did Bio-Path Holdings do a reverse stock split?

Our latest story on this, dated May 26, 2026: "Bio-Path cancels planned reverse split and approves treasury plan". The story links the filing or release it is based on. Read the story.

Was Bio-Path Holdings delisted?

Our latest story on this, dated Jul 11, 2025: "Nasdaq files Form 25 to remove Bio-Path Holdings common stock from listing". The story links the filing or release it is based on. Read the story.

Has Bio-Path Holdings raised money recently?

Our latest story on this, dated Jul 16, 2026: "Bio-Path sells small Regulation A lots and hires a strategic advisor". The story links the filing or release it is based on. Read the story.

What is the ticker symbol of Bio-Path Holdings?

Bio-Path Holdings, Inc. trades under the ticker BPTH on OTC.

Where is Bio-Path Holdings listed?

Bio-Path Holdings, Inc. is listed on OTC.

What is the SEC CIK of Bio-Path Holdings?

The SEC Central Index Key (CIK) for Bio-Path Holdings, Inc. is 1133818. Its filings are on SEC EDGAR.

How many shares does Bio-Path Holdings have outstanding?

50,297,451 shares as of 2026-05-20, per the cover page of its 10-Q filed 2026-05-20.

Which country or territory is Bio-Path Holdings listed under?

Our directory records Bio-Path Holdings, Inc. under United States.

What does Bio-Path Holdings do?

Our directory classifies Bio-Path Holdings, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Bio-Path Holdings?

The ISIN recorded for Bio-Path Holdings, Inc. is US09057N4097.

Does aibio.space cover Bio-Path Holdings?

aibio.space lists Bio-Path Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Bio-Path Holdings incorporated?

SEC records list its state or country of incorporation as WY.

Is Bio-Path Holdings profitable?

Bio-Path Holdings, Inc. reported a net loss of $9.9 million for the fiscal year ended Dec 31, 2024, and used $10.6 million of cash in operations, per its annual report to the SEC.

How much does Bio-Path Holdings spend on research and development?

$7.3 million in the fiscal year ended Dec 31, 2024, per its annual report.

How much cash does Bio-Path Holdings have?

$12,000 in cash at Mar 31, 2026, per its 10-Q.

Investor discussion: Bio-Path Holdings

Members talk about Bio-Path Holdings (BPTH). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Bio-Path Holdings, newest first. Each line links the filing it comes from.

  1. Listings

    Reported a reverse stock split. SEC Form 8-K (Items 7.01,8.01,9.01). Source

  2. Listings

    Filed to end its SEC reporting. SEC Form 15-12G. Source

  3. Distress

    Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source

  4. Listings

    Reported a reverse stock split. SEC Form 8-K (Items 5.01,5.03,7.01,8.01). Source

  5. Distress

    Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source

  6. Distress

    Reported substantial doubt about its ability to continue as a going concern. SEC Form 8-K (Items 5.02,8.01). Source

  7. Legal

    Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source

  8. Listings

    Filed to remove its shares from exchange listing. SEC Form 25-NSE. Source

  9. Distress

    Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source

  10. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source

  11. Financings

    Filed a registration statement for a share offering. SEC Form S-1. Source

  12. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,5.02,5.07,9.01). Source

  13. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open OTC:BPTH on TradingView.

SEC filings and registration

SEC name
Bio-Path Holdings, Inc.
CIK
1133818
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
BPTH (OTC)
State or country of incorporation
WY
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company
Business address
4710 BELLAIRE BOULEVARD, BELLAIRE, TX, 77401
Phone
(832) 742-1357
Shares outstanding
50,297,451 as of 2026-05-20 (10-Q filed 2026-05-20)
Former names
BIO-PATH HOLDINGS INC; OGDEN GOLF CO CORP

Recent filings (8-K and 6-K are the company's own announcements)

  • 8-K filed 2026-07-16
  • 8-K filed 2026-05-26
  • 10-Q filed 2026-05-20
  • 8-K filed 2026-03-20
  • 8-K filed 2026-02-24
  • 10-Q filed 2026-01-13
  • 8-K filed 2025-11-14
  • 8-K filed 2025-10-29

Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Listing details

Bio-Path Holdings, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker BPTH, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Bio-Path Holdings, Inc.
Ticker
BPTH
Listing
OTC
Country or territory
United States
Business scope
Biotechnology
ISIN
US09057N4097
Last quote in directory
2026-10-21
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.